Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial-Reference-Cited by-同舟云学术

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Published:2019-05 Issue:10185 Volume:393 Page:2051-2058
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Palma David A,Olson Robert,Harrow Stephen,Gaede Stewart,Louie Alexander V,Haasbeek Cornelis,Mulroy Liam,Lock Michael,Rodrigues George B,Yaremko Brian P,Schellenberg Devin,Ahmad Belal,Griffioen Gwendolyn,Senthi Sashendra,Swaminath Anand,Kopek Neil,Liu Mitchell,Moore Karen,Currie Suzanne,Bauman Glenn S,Warner Andrew,Senan Suresh

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2012

2. Non-small cell lung cancer, version 5. 2017, NCCN clinical practice guidelines in oncology;Ettinger;J Natl Compr Canc Netw,2017

3. Oligometastases;Hellman;J Clin Oncol,1995

4. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy;Barney;J Urol,1939

5. The oligometastatic state—separating truth from wishful thinking;Palma;Nat Rev Clin Oncol,2014

Cited by 1456 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma;Journal of Clinical and Experimental Hepatology;2025-01

2. Exploring Radiotherapy as a Promising Alternative for Managing Advanced Upper Tract Urothelial Carcinoma: Rescuing Chemotherapy-Intolerant Patients;Clinical Genitourinary Cancer;2024-12

3. Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-11

4. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort;Radiotherapy and Oncology;2024-10

5. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics;Radiotherapy and Oncology;2024-10